(RTTNews) - MediWound Ltd. (MDWD), enzymatic therapeutics for tissue repair, on Tuesday announced it will host a virtual Key Opinion Leader (KOL) event on January 8, 2025, at 10:00 AM ET.
The event will focus on EscharEx, an innovative biologic drug in late-stage development for chronic wound debridement, specifically targeting Venous Leg Ulcers (VLUs).
The event will feature three distinguished clinical experts: Dr. John C. Lantis II, Dr. Vickie R. Driver, and Dr. Robert J. Snyder.
These experts will discuss promising Phase II results of EscharEx, its effectiveness in wound debridement, and the upcoming Phase III VALUE study in VLUs. They will also highlight EscharEx's competitive advantages and its unique commercial opportunity, addressing the substantial unmet need for better treatment options in chronic wound care.
In addition, MediWound will share details on the upcoming Phase II/III study focused on diabetic foot ulcers (DFUs).
The virtual event will include a live Q&A session with MediWound's leadership team, providing an opportunity for participants to engage with experts and ask questions.
MDWD closed Tuesday's (Dec. 17, 2024) trading at $17.27, up 3.10%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
